1. Pisani, P., Parkin, D. M., Bray, F. & Ferlay, J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 83(1), 18-29 (1999).
2. 厚生労働省、人口動態調査 http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai15/index.html. (2015).
3. May, F. E., Semple, J. I. & Westley. B. R. The human two domain trefoil protein, TFF2, is glycosylated in vivo in the stomach. Gut. 46(4), 454-9 (2000).
4. May, F.E., Church S. T., Major, S. & Westley, B. R. The closely related estrogen- regulated trefoil proteins TFF1 and TFF3 have markedly different hydrodynamic properties, overall charge, and distribution of surface charge. Biochemistry. 42(27), 8250-9 (2003).
5. Williams, G. R. & Wright, N. A. Trefoil factor family domain peptides. Virchows Arch. 431(5), 299-304 (1997).
6. Kjellev, S. The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life Sci. 66(8), 1350-69 (2009).
7. Plaut, A.G. Trefoil peptides in the defense of the gastrointestinal tract. N Engl J Med. 336(7), 506-7 (1997).
8. Stephane, R., Catherine, T. and Marie, C. R. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta. 1378(1), F61-77 (1998).
9. Blaser, M. J. & Parsonnet, J. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest. 94(1), 4-8 (1994).
10. Masiakowski, P., Breathnach, R., Bloch, J., Gannon, F., Krust, A., et al. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res. 10(24), 7895-903 (1982).
11. Poulsom, R., Hanby, A.M., Lalani, E.N., Hauser, F., Hoffmann, W., et al. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol. 183(1), 30-8 (1997).
12. Rio, M. C., Bellocq, J. P., Gairard, B., Rasmussen, U.B., Krust, A., et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci U S A. 84(24), 9243-7 (1987).
13. May, F. E. & Westley, B. R. TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocr Relat Cancer. 22(3), 465-79 (2015).
14. Henry, J. A., Bennett, M. K., Piggott, N. H., Levett, D. L., May, F. E., et al. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer. 64(4), 677-82 (1991).
15. May, F. E. & Westley, B. R. Trefoil proteins: their role in normal and malignant cells. J Pathol. 183(1), 4-7 (1997).
16. Longman, R. J., Thomas, M. G. & Poulsom, R. Trefoil peptides and surgical disease. Br J Surg. 86(6), 740-8 (1999).
17. Ahmed, A. R., Griffiths, A. B., Tilby, M. T., Westley, B. R. & May, F. E. TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol. 180(3), 904-16 (2012).
18. Aikou, S., Ohmoto, Y., Gunji, T., Matsuhashi, N., Ohtsu, H., et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 141(3), 837-845 e1-7 (2011).
19. Else, M. V., Michael, B., Steen, S. P., Ebba, N. & Niels, T. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 12(3 Pt 1), 807-12 (2006).
20. Yiqing, Qu., Yie, Y., Dedong, Ma. & Wei, X. Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep. 27(4), 1277-83 (2012).
21. Muenphon, K., Limpaiboon, T., Jearanaikoon, P., Pairoikul, C., Stripa, B., et al. Amplification of chromosome 21q22.3 harboring trefoil factor family genes in liver fluke related cholangiocarcinoma is associated with poor prognosis. World J Gastroenterol. 12(26), 4143-8 (2006).
22. Wang, X.N., Wang, S. J., Pandey, V., Chen, P., Li, Q., et al. Trefoil factor 3 as a novel biomarker to distinguish between adenocarcinoma and squamous cell carcinoma. Medicine (Baltimore). 94(20), e860 (2015).
23. Vocka, M., Langer, D., Petrtyl, J., Vockova, P., Hanus, T., et al. Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. Neoplasma. 62(3), 470-7 (2015).
24. Davidson, B., Stavnes, H.T., Risberg, B., Nesland, J. M., Wohlschlaeger, J., et al. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. Hum Pathol. 43(5), 684-94 (2012).
25. Lasa, A., Garcia, A., Alonso, C., Milet, P., Cornet, M., et al. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One. 8(9), e74079 (2013).
26. Huang, Y. G., Li, Y. F., Pan, B. L., Wang, L. P., Zhang, Y., et al. Trefoil factor 1 gene alternations and expression in colorectal carcinomas. Tumori. 99(6), 702-7 (2013).
27. Huang, Z., Zhang, X., Lu, H. & Ding, H. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC Gastroenterol. 14, 74 (2014).
28. McCarty, K. S. Jr., Miller, L. S., Cox, E. B., Konrath, J. & McCarty, K. S. Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 109(8), 716-21 (1985).
29. Lee, C.S., Taib, N. A., Ashrafzadeh, A., Fadzli, F., Harun, F., et al. Unmasking Heavily O-Glycosylated Serum Proteins Using Perchloric Acid: Identification of Serum Proteoglycan 4 and Protease C1 Inhibitor as Molecular Indicators for Screening of Breast Cancer. PLoS One. 11(2), e0149551 (2016).
30. Hao, W., Zhang, X., Xiu, B., Yang, X., Hu, S., et al. Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients. Tumour Biol. 37(7), 8909-16 (2016).
31. Shimomura, A., Shiino, S., Kawauchi, J., Takizawa, S., Sakamoto, H., et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 107(3), 326-34 (2016).
32. Tomasetto, C., Rio, M. C., Gautier, C., Wolf, C., Hareuveni, M., et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J. 9(2), 407-14 (1990).
33. May, F. E., Semple, J. I., Prest, S. J., & Westley, B. R. Expression and motogenic activity of TFF2 in human breast cancer cells. Peptides. 25(5), 865-72 (2004).
34. Taupin, D., Wu, D. C., Jeon, W. K., Devanev, K., Wang, T. C., et al. The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J Clin Invest. 103(9), R31-8 (1999).
35. Miller, W. R. & Larionov, A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 12(4), R52 (2010).
36. Lefebvre, O., Chenard, M. P., Masson, R., Linares, J., Dierich, A., et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 274(5285), 259-62 (1996).
37. Markicćević, M., Džodić, R., Buta, M., Kanjer, K., Mandušić, V., et al. Trefoil factor 1 in early breast carcinoma: a potential indicator of clinical outcome during the first 3 years of follow-up. Int J Med Sci. 11(7), 663-73 (2014).
38. Thomsen, K. G., Lyng, M. B., Elias, D., Vever, H., Knoop, A.S., et al. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients. Breast Cancer Res Treat. 154(3), 483-94 (2015).
39. Buache, E., Etique, N., Alpy, F., Stoll, I., Muckenstum, M,. et al. Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene 30(29), 3261- 73 (2011).
40. Elia, G., Chinery, R., Hanby, A. M., Poulsom, R. & Wright, N. A. The production and characterization of a new monoclonal antibody to the trefoil peptide human spasmolytic polypeptide. Histochem J. 26(8), 644-7 (1994).
41. Nomura, S., Baxter, T., Yamaguchi, H., Leys, C., Vartapetian, A. B., et al. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis- infected mice. Gastroenterology. 127(2), 582-94 (2004).
42. Nomura, S., Settle, S. H., Leys, C. M., Means, A. L., Peek, R. M., et al. Evidence for repatterning of the gastric fundic epithelium associated with Menetrier's disease and TGFalpha overexpression. Gastroenterology. 128(5), 1292-305 (2005).
43. Nomura, S., Yamaguchi, H., Ogawa, M., Wang, T. C., Lee, J. R., et al. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol. 288(2), G362-75 (2005).
44. Yoshizawa, N., Takenaka, Y., Yamaguchi, H., Tetsuya, T., Tanaka, H., et al. Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. Lab Invest. 87(12), 1265-76 (2007).